{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:53:38Z","timestamp":1791312818792,"version":"4.3.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010489","name":"Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007179","name":"Advanced Centre for Treatment Research and Education in Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007179","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.yexcr.2025.114870","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:43:47Z","timestamp":1766130227000},"page":"114870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["p38 MAPK-mediated suppression of Nrf2-MPC2 axis drives metabolic reprogramming which confers imatinib resistance in blast crisis phase of chronic myeloid leukemia"],"prefix":"10.1016","volume":"455","author":[{"given":"Manish","family":"Bhat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mythreyi","family":"Narasimhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Shelar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavendra","family":"Patwardhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh Kumar","family":"Sandur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukmini","family":"Govekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2025.114870_bib1","first-page":"1","article-title":"Chronic myeloid leukemia\u2014a brief history","author":"Melo","year":"2007","journal-title":"Myeloproliferative Disorders"},{"issue":"10","key":"10.1016\/j.yexcr.2025.114870_bib2","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.yexcr.2025.114870_bib3","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.3324\/haematol.2009.010629","article-title":"High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the international randomized study of interferon and STI571 (IRIS) trial","volume":"94","author":"Guilhot","year":"2009","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.yexcr.2025.114870_bib4","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-Year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.yexcr.2025.114870_bib5","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114870_bib6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JGO.2015.002667","article-title":"Chronic myeloid leukemia in India","volume":"3","author":"Ganesan","year":"2017","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.yexcr.2025.114870_bib7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.yexcr.2025.114870_bib8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3390\/cancers14030620","article-title":"Genomic mechanisms influencing outcome in chronic myeloid leukemia","volume":"14","author":"Fernandes","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.yexcr.2025.114870_bib9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","article-title":"Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options","volume":"13","author":"Jabbour","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"10","key":"10.1016\/j.yexcr.2025.114870_bib10","first-page":"3530","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"5","key":"10.1016\/j.yexcr.2025.114870_bib11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/bjh.18370","article-title":"Treatment of blast phase chronic myeloid leukaemia: a rare and challenging entity","volume":"199","author":"Copland","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.yexcr.2025.114870_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2016.10.005","article-title":"Management of CML-blast crisis","volume":"29","author":"Hehlmann","year":"2016","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114870_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/nyas.14298","article-title":"Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation","volume":"1467","author":"Lu","year":"2020","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.yexcr.2025.114870_bib14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12079-021-00647-x","article-title":"Atypical activation of signaling downstream of inactivated Bcr-Abl mediates chemoresistance in chronic myeloid leukemia","volume":"16","author":"Narasimhan","year":"2022","journal-title":"J. Cell Commun. Signal."},{"key":"10.1016\/j.yexcr.2025.114870_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116307","article-title":"The interplay of p38 MAPK signaling and mitochondrial metabolism, a dynamic target in cancer and pathological contexts","volume":"225","author":"Sarg","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.yexcr.2025.114870_bib16","series-title":"Cell Viability Assays","author":"Riss","year":"2016"},{"issue":"2","key":"10.1016\/j.yexcr.2025.114870_bib17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jchromb.2008.04.030","article-title":"A sample extraction and chromatographic strategy for increasing LC\/MS detection coverage of the erythrocyte metabolome","volume":"871","author":"Sana","year":"2008","journal-title":"J. Chromatogr., B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.yexcr.2025.114870_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.abst.2025.01.004","article-title":"Genomic analysis identifies an incipient signature to forecast imatinib resistance before start of treatment in patients with chronic myeloid leukemia","volume":"7","author":"Mojidra","year":"2025","journal-title":"Advances in Biomarker Sciences and Technology"},{"issue":"10","key":"10.1016\/j.yexcr.2025.114870_bib19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrc3365","article-title":"Mitochondria and cancer","volume":"12","author":"Wallace","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.yexcr.2025.114870_bib20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","article-title":"Targeting cancer metabolism in the era of precision oncology","volume":"21","author":"Stine","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.yexcr.2025.114870_bib21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/metabo5040571","article-title":"Cancer metabolism and drug resistance","volume":"5","author":"Rahman","year":"2015","journal-title":"Metabolites"},{"key":"10.1016\/j.yexcr.2025.114870_bib22","series-title":"Metabolic Alterations in Cancer and their Potential as Therapeutic Targets","year":"2017"},{"issue":"17","key":"10.1016\/j.yexcr.2025.114870_bib23","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.7150\/jca.21125","article-title":"The glycolytic switch in tumors: how many players are involved?","volume":"8","author":"Yu","year":"2017","journal-title":"J. Cancer"},{"issue":"4","key":"10.1016\/j.yexcr.2025.114870_bib24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41419-023-05811-2","article-title":"BCR-ABL triggers a glucose-dependent survival program during leukemogenesis through the suppression of TXNIP","volume":"14","author":"Feng","year":"2023","journal-title":"Cell Death Dis."},{"issue":"10","key":"10.1016\/j.yexcr.2025.114870_bib25","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/nm.4399","article-title":"Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells","volume":"23","author":"Kuntz","year":"2017","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114870_bib26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s43556-020-00012-1","article-title":"Cancer metabolism and intervention therapy","volume":"2","author":"Zhao","year":"2021","journal-title":"Molecular Biomedicine"},{"issue":"10","key":"10.1016\/j.yexcr.2025.114870_bib27","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1158\/1078-0432.CCR-08-3291","article-title":"Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells","volume":"15","author":"Kominsky","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.yexcr.2025.114870_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021924","article-title":"Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells","volume":"6","author":"Kluza","year":"2011","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.yexcr.2025.114870_bib29","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1038\/onc.2010.67","article-title":"Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1\u03b1-induced metabolic reprograming","volume":"29","author":"Zhao","year":"2010","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.yexcr.2025.114870_bib30","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1128\/MCB.25.12.4853-4862.2005","article-title":"Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling","volume":"25","author":"Emerling","year":"2005","journal-title":"Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.yexcr.2025.114870_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101684","article-title":"Pyruvate kinase M2 coordinates metabolism switch between glycolysis and glutaminolysis in cancer cells","volume":"23","author":"Li","year":"2020","journal-title":"iScience"},{"issue":"12","key":"10.1016\/j.yexcr.2025.114870_bib32","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41375-021-01315-0","article-title":"Metabolic alterations mediated by STAT3 promotes drug persistence in CML","volume":"35","author":"Patel","year":"2021","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.yexcr.2025.114870_bib33","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1182\/blood.V120.21.4318.4318","article-title":"The expression profile of glycolysis associated molecules and chemoresistance in acute myeloid leukemia","volume":"120","author":"Song","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.yexcr.2025.114870_bib34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.tibs.2016.01.002","article-title":"Pyruvate and metabolic flexibility: illuminating a path toward selective cancer therapies","volume":"41","author":"Olson","year":"2016","journal-title":"Trends Biochem. Sci."},{"issue":"4","key":"10.1016\/j.yexcr.2025.114870_bib35","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/cells10040762","article-title":"The metabolic fates of pyruvate in normal and neoplastic cells","volume":"10","author":"Prochownik","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.yexcr.2025.114870_bib36","article-title":"Lactate in the tumor microenvironment: a rising star for targeted tumor therapy","volume":"10","author":"Li","year":"2023","journal-title":"Front. Nutr."},{"key":"10.1016\/j.yexcr.2025.114870_bib37","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3389\/fonc.2019.01143","article-title":"Lactate in the regulation of tumor microenvironment and therapeutic approaches","volume":"9","author":"de la Cruz-Lopez","year":"2019","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.yexcr.2025.114870_bib38","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3390\/biom11040610","article-title":"Relationship between oxidative stress and imatinib resistance in model chronic myeloid leukemia cells","volume":"11","author":"G\u0142owacki","year":"2021","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.yexcr.2025.114870_bib39","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1038\/cddis.2012.111","article-title":"Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence","volume":"3","author":"Drullion","year":"2012","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114870_bib40","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1038\/s41467-023-40222-z","article-title":"Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells","volume":"14","author":"Rattigan","year":"2023","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.yexcr.2025.114870_bib41","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/1873-3468.14993","article-title":"Nrf2 as a regulator of energy metabolism and mitochondrial function","volume":"598","author":"Luchkova","year":"2024","journal-title":"FEBS Lett."},{"issue":"5","key":"10.1016\/j.yexcr.2025.114870_bib42","doi-asserted-by":"crossref","first-page":"E763","DOI":"10.1210\/jc.2010-2642","article-title":"Proteasome inhibition induces a p38 MAPK pathway-dependent antiapoptotic program via Nrf2 in thyroid cancer cells","volume":"96","author":"Du","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.yexcr.2025.114870_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2021.152804","article-title":"Redox-sensitive Nrf2 and MAPK signaling pathways contribute to trichloroethene-mediated autoimmune disease progression","volume":"457","author":"Banerjee","year":"2021","journal-title":"Toxicology"},{"issue":"6","key":"10.1016\/j.yexcr.2025.114870_bib44","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1158\/1078-0432.CCR-14-2146","article-title":"Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations","volume":"21","author":"Alvarez-Calderon","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.yexcr.2025.114870_bib45","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.yexcr.2025.114870_bib46","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3324\/haematol.2017.166280","article-title":"Chronic myeloid leukemia: room for improvement?","volume":"102","author":"Baccarani","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.yexcr.2025.114870_bib47","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1634\/theoncologist.2012-0197","article-title":"Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in Japan and the U.S","volume":"17","author":"Chihara","year":"2012","journal-title":"Oncologist"}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482725004707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482725004707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:08:17Z","timestamp":1773950897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482725004707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0014482725004707"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2025.114870","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"p38 MAPK-mediated suppression of Nrf2-MPC2 axis drives metabolic reprogramming which confers imatinib resistance in blast crisis phase of chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2025.114870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114870"}}